The Biden Administration initially proposed allowing Medicare to cover GLP-1 obesity drugs in Part D, but CMS decided not to proceed with broad weight-loss coverage in early 2025, citing the $40 billion over 10 years projected cost ( [65] ) ( [21] )
Borras C, editor
But medication is just one piece of the puzzle
Tirzepatide is newer, but it may lead to greater weight loss for some people because of its dual hormone action
Studies on rodents and cells suggest that BPC-157 might help heal tissues like tendons, joints, nerves, the intestinal tract, stomach and skin, but these havent been supported by studies in humans
Smaller, more frequent meals distribute nutrition throughout the day while avoiding the discomfort of larger portions sitting in a slowly-emptying stomach